Venus Medtech (Hangzhou) Inc. (VMTHF)
- CNW Group
Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.
Venus Medtech (02500. HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced today that its in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, VenusP-Valve, has completed its first implantation in the PROTEUS IDE Pivotal Clinical Study at the University of Virginia School of Medicine. This momentous procedure was performed by a multidisciplinary team coordinated by Prof. Scott Lim and Prof. Mich
- CNW Group
Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval
Venus Medtech (02500. HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced today that, VenusP-Valve, the company's in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, cleared approval from Health Canada.
- PR Newswire
Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023
Venus Medtech is changing how the world treats structural heart disease. The company will present its products at its booth (#28), during two symposia, in multiple podium presentations and at a special cocktail reception where it will officially launch the SMART-ALIGN multicenter clinical study.
